Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.
—
Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.
—
Daily adjusted close
Aequus Pharmaceuticals Inc. is a specialized pharmaceutical firm based in Vancouver, Canada, dedicated to the development and commercialization of medicinal products across the country. The company concentrates its efforts on several key medical disciplines, including neurological conditions, ophthalmology, and transplantation medicine. Its current commercial portfolio features: Vistitan, an ophthalmic solution designed to lower elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Tacrolimus IR, an immunosuppressive drug prescribed for the management and prevention of acute organ rejection subsequent to transplantation procedures. The Evolve range of dry eye products, formulated to alleviate various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness. Additional preservative-free ophthalmic products. In its development pipeline, Aequus is advancing: Extended-release oral tablet formulations of Topiramate XR and Oxcarbazepine XR, both intended for the treatment of epilepsy. AQS1303, a transdermal patch containing pyridoxine/doxylamine, aimed at addressing nausea and vomiting during pregnancy. AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. Aequus Pharmaceuticals has forged strategic alliances with other industry players, including Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for the marketing of extended-release anti-epileptic medications; and Medicom Healthcare Ltd., with whom they collaborate on preservative-free treatments within ophthalmology. The company was established in 2013.